• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型嘧啶-喹诺酮杂合物作为新型乳酸脱氢酶A(LDHA)抑制剂的设计与合成

Design and Synthesis of New Pyrimidine-Quinolone Hybrids as Novel LDHA Inhibitors.

作者信息

Díaz Iván, Salido Sofia, Nogueras Manuel, Cobo Justo

机构信息

Facultad de Ciencias Experimentales, Departamento de Química Inorgánica y Orgánica, Universidad de Jaén, E-23071 Jaén, Spain.

出版信息

Pharmaceuticals (Basel). 2022 Jun 24;15(7):792. doi: 10.3390/ph15070792.

DOI:10.3390/ph15070792
PMID:35890090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9322123/
Abstract

A battery of novel pyrimidine-quinolone hybrids was designed by docking scaffold replacement as lactate dehydrogenase A (hLDHA) inhibitors. Structures with different linkers between the pyrimidine and quinolone scaffolds (10-21 and 24−31) were studied in silico, and those with the 2-aminophenylsulfide (U-shaped) and 4-aminophenylsulfide linkers (24−31) were finally selected. These new pyrimidine-quinolone hybrids (24−31)(a−c) were easily synthesized in good to excellent yields by a green catalyst-free microwave-assisted aromatic nucleophilic substitution reaction between 3-(((2/4-aminophenyl)thio)methyl)quinolin-2(1H)-ones 22/23(a−c) and 4-aryl-2-chloropyrimidines (1−4). The inhibitory activity against hLDHA of the synthesized hybrids was evaluated, resulting IC50 values of the U-shaped hybrids 24−27(a−c) much better than the ones of the 1,4-linked hybrids 28−31(a−c). From these results, a preliminary structure−activity relationship (SAR) was established, which enabled the design of novel 1,3-linked pyrimidine-quinolone hybrids (33−36)(a−c). Compounds 35(a−c), the most promising ones, were synthesized and evaluated, fitting the experimental results with the predictions from docking analysis. In this way, we obtained novel pyrimidine-quinolone hybrids (25a, 25b, and 35a) with good IC50 values (<20 μM) and developed a preliminary SAR.

摘要

通过对接支架替换设计了一系列新型嘧啶 - 喹诺酮杂化物作为乳酸脱氢酶A(hLDHA)抑制剂。对嘧啶和喹诺酮支架之间具有不同连接基的结构(10 - 21和24−31)进行了计算机模拟研究,最终选择了具有2 - 氨基苯硫醚(U形)和4 - 氨基苯硫醚连接基的结构(24−31)。这些新型嘧啶 - 喹诺酮杂化物(24−31)(a - c)通过3 - (((2/4 - 氨基苯基)硫代)甲基)喹啉 - 2(1H) - 酮22/23(a - c)与4 - 芳基 - 2 - 氯嘧啶(1 - 4)之间的绿色无催化剂微波辅助芳族亲核取代反应,以良好至优异的产率轻松合成。评估了合成杂化物对hLDHA的抑制活性,结果表明U形杂化物24−27(a - c)的IC50值比1,4 - 连接杂化物28−31(a - c)的IC50值好得多。根据这些结果,建立了初步的构效关系(SAR),这使得能够设计新型1,3 - 连接的嘧啶 - 喹诺酮杂化物(33−36)(a - c)。合成并评估了最有前景的化合物35(a - c),实验结果与对接分析的预测相符。通过这种方式,我们获得了具有良好IC50值(<20μM)的新型嘧啶 - 喹诺酮杂化物(25a、25b和35a),并建立了初步的SAR。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/3fe9adc186cf/pharmaceuticals-15-00792-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/7724237a0424/pharmaceuticals-15-00792-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/366f9bb773f2/pharmaceuticals-15-00792-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/bfe130f7c331/pharmaceuticals-15-00792-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/8ee8144877c4/pharmaceuticals-15-00792-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/1cb1f8c22820/pharmaceuticals-15-00792-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/c758b92ebe4c/pharmaceuticals-15-00792-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/d3ec80e37c18/pharmaceuticals-15-00792-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/71621f06d857/pharmaceuticals-15-00792-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/b5ad50916ea4/pharmaceuticals-15-00792-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/3582cbb90524/pharmaceuticals-15-00792-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/4c9368d885c4/pharmaceuticals-15-00792-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/783cb7696135/pharmaceuticals-15-00792-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/397dc5d7b3fd/pharmaceuticals-15-00792-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/8dd897b5354d/pharmaceuticals-15-00792-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/54c48f2108c6/pharmaceuticals-15-00792-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/4a76f21aa87a/pharmaceuticals-15-00792-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/80086c157413/pharmaceuticals-15-00792-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/3fe9adc186cf/pharmaceuticals-15-00792-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/7724237a0424/pharmaceuticals-15-00792-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/366f9bb773f2/pharmaceuticals-15-00792-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/bfe130f7c331/pharmaceuticals-15-00792-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/8ee8144877c4/pharmaceuticals-15-00792-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/1cb1f8c22820/pharmaceuticals-15-00792-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/c758b92ebe4c/pharmaceuticals-15-00792-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/d3ec80e37c18/pharmaceuticals-15-00792-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/71621f06d857/pharmaceuticals-15-00792-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/b5ad50916ea4/pharmaceuticals-15-00792-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/3582cbb90524/pharmaceuticals-15-00792-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/4c9368d885c4/pharmaceuticals-15-00792-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/783cb7696135/pharmaceuticals-15-00792-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/397dc5d7b3fd/pharmaceuticals-15-00792-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/8dd897b5354d/pharmaceuticals-15-00792-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/54c48f2108c6/pharmaceuticals-15-00792-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/4a76f21aa87a/pharmaceuticals-15-00792-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/80086c157413/pharmaceuticals-15-00792-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece0/9322123/3fe9adc186cf/pharmaceuticals-15-00792-g014.jpg

相似文献

1
Design and Synthesis of New Pyrimidine-Quinolone Hybrids as Novel LDHA Inhibitors.新型嘧啶-喹诺酮杂合物作为新型乳酸脱氢酶A(LDHA)抑制剂的设计与合成
Pharmaceuticals (Basel). 2022 Jun 24;15(7):792. doi: 10.3390/ph15070792.
2
Synthesis of Ethyl Pyrimidine-Quinolincarboxylates Selected from Virtual Screening as Enhanced Lactate Dehydrogenase (LDH) Inhibitors.从虚拟筛选中选择的嘧啶-喹啉羧酸乙酯的合成作为增强的乳酸脱氢酶 (LDH) 抑制剂。
Int J Mol Sci. 2024 Sep 9;25(17):9744. doi: 10.3390/ijms25179744.
3
Synthesis and LDH Inhibitory Activity of Analogues to Natural Products with 2,8-Dioxabicyclo[3.3.1]nonane Scaffold.具有 2,8-二氧杂双环[3.3.1]壬烷支架的天然产物类似物的合成及 LDH 抑制活性。
Int J Mol Sci. 2023 Jun 8;24(12):9925. doi: 10.3390/ijms24129925.
4
Structural Modifications of Diarylpyrimidine-quinolone Hybrids as Potent HIV-1 NNRTIs with an Improved Drug Resistance Profile.作为具有改善耐药性的强效HIV-1非核苷类逆转录酶抑制剂的二芳基嘧啶-喹诺酮杂化物的结构修饰
Curr Pharm Des. 2016;22(46):6982-6987. doi: 10.2174/1381612823666161122125657.
5
Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors.设计并合成喹啉-嘧啶杂合衍生物作为潜在的疟原虫抑制剂。
Eur J Med Chem. 2021 May 5;217:113330. doi: 10.1016/j.ejmech.2021.113330. Epub 2021 Mar 3.
6
Novel tacrine-based acetylcholinesterase inhibitors as potential agents for the treatment of Alzheimer's disease: Quinolotacrine hybrids.新型他克林类乙酰胆碱酯酶抑制剂有望成为治疗阿尔茨海默病的药物:喹喔啉他克林杂合体。
Mol Divers. 2022 Feb;26(1):489-503. doi: 10.1007/s11030-021-10307-2. Epub 2021 Sep 7.
7
Design and Synthesis of Thiazole Scaffold-Based Small Molecules as Anticancer Agents Targeting the Human Lactate Dehydrogenase A Enzyme.基于噻唑骨架的小分子作为靶向人乳酸脱氢酶A酶的抗癌剂的设计与合成。
ACS Omega. 2023 May 10;8(20):17552-17562. doi: 10.1021/acsomega.2c07569. eCollection 2023 May 23.
8
New Route to the Synthesis of Novel Pyrazolo[1,5-a]pyrimidines and Evaluation of their Antimicrobial Activity as RNA Polymerase Inhibitors.新型吡唑并[1,5-a]嘧啶类化合物的合成新途径及其作为 RNA 聚合酶抑制剂的抗菌活性评价。
Med Chem. 2022;18(9):926-948. doi: 10.2174/1573406418666220302092414.
9
Synthesis, Cytotoxicity, ADMET and Molecular Docking Studies of Some Quinoline-Pyrimidine Hybrid Compounds: 3-(2-Amino-6-arylpyrimidin-4- yl)-4-hydroxy-1-methylquinolin-2(1H)-ones.一些喹啉-嘧啶杂合化合物的合成、细胞毒性、ADMET 和分子对接研究:3-(2-氨基-6-芳基嘧啶-4-基)-4-羟基-1-甲基喹啉-2(1H)-酮。
Med Chem. 2022;18(1):36-50. doi: 10.2174/1573406417666201230092615.
10
Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell growth inhibition studies.酰胺衍生的嘧啶-苯并咪唑杂合体作为微管蛋白抑制剂:合成、计算机模拟和细胞生长抑制研究。
Bioorg Chem. 2021 May;110:104765. doi: 10.1016/j.bioorg.2021.104765. Epub 2021 Feb 24.

引用本文的文献

1
Synthesis and LDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria.用于原发性高草酸尿症的新型司替戊醇相关化合物的合成及乳酸脱氢酶A抑制活性
Int J Mol Sci. 2024 Dec 10;25(24):13266. doi: 10.3390/ijms252413266.
2
Tracking Selective Internalization and Intracellular Dynamics of Modified Chitosan Polymeric Micelles of Interest in Primary Hyperoxaluria Diseases.追踪原发性高草酸尿症相关修饰壳聚糖聚合物胶束的选择性内化及细胞内动力学
ACS Omega. 2024 Sep 10;9(38):39503-39512. doi: 10.1021/acsomega.4c03415. eCollection 2024 Sep 24.
3
Synthesis of Ethyl Pyrimidine-Quinolincarboxylates Selected from Virtual Screening as Enhanced Lactate Dehydrogenase (LDH) Inhibitors.

本文引用的文献

1
Preliminary Studies of Antimicrobial Activity of New Synthesized Hybrids of 2-Thiohydantoin and 2-Quinolone Derivatives Activated with Blue Light.新型 2-硫代海因和 2-喹诺酮衍生物的蓝光激活杂合抗菌活性的初步研究。
Molecules. 2022 Feb 5;27(3):1069. doi: 10.3390/molecules27031069.
2
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.在原发性高草酸尿症的首次人体 1 期 PHYOX1(nedosiran)研究中,安全性、药效学和暴露-反应建模结果。
Kidney Int. 2022 Mar;101(3):626-634. doi: 10.1016/j.kint.2021.08.015. Epub 2021 Sep 2.
3
从虚拟筛选中选择的嘧啶-喹啉羧酸乙酯的合成作为增强的乳酸脱氢酶 (LDH) 抑制剂。
Int J Mol Sci. 2024 Sep 9;25(17):9744. doi: 10.3390/ijms25179744.
4
Synthesis and LDH Inhibitory Activity of Analogues to Natural Products with 2,8-Dioxabicyclo[3.3.1]nonane Scaffold.具有 2,8-二氧杂双环[3.3.1]壬烷支架的天然产物类似物的合成及 LDH 抑制活性。
Int J Mol Sci. 2023 Jun 8;24(12):9925. doi: 10.3390/ijms24129925.
Design, Synthesis and Anticancer Evaluation of Substituted Cinnamic Acid Bearing 2-Quinolone Hybrid Derivatives.
取代肉桂酸类 2-喹诺酮杂合衍生物的设计、合成与抗癌活性评价。
Molecules. 2021 Aug 4;26(16):4724. doi: 10.3390/molecules26164724.
4
Structure activity relationships and the binding mode of quinolinone-pyrimidine hybrids as reversal agents of multidrug resistance mediated by P-gp.作为 P-糖蛋白介导的多药耐药性的逆转剂,喹啉酮-嘧啶类混合物的构效关系和结合模式。
Sci Rep. 2021 Aug 19;11(1):16856. doi: 10.1038/s41598-021-96226-6.
5
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.嘧啶类表皮生长因子受体酪氨酸激酶抑制剂在肿瘤靶向治疗中的应用。
Eur J Med Chem. 2021 Oct 5;221:113523. doi: 10.1016/j.ejmech.2021.113523. Epub 2021 May 4.
6
Targeting lactate dehydrogenase a improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench.靶向乳酸脱氢酶A可提高非小细胞肺癌的放疗疗效:从临床到实验室研究
J Transl Med. 2021 Apr 26;19(1):170. doi: 10.1186/s12967-021-02825-2.
7
Cancer statistics for the year 2020: An overview.2020年癌症统计数据概述。
Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.
8
Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors.设计并合成喹啉-嘧啶杂合衍生物作为潜在的疟原虫抑制剂。
Eur J Med Chem. 2021 May 5;217:113330. doi: 10.1016/j.ejmech.2021.113330. Epub 2021 Mar 3.
9
A hidden cause of oxalate nephropathy: a case report.草酸钙肾病的一个隐匿病因:病例报告
J Med Case Rep. 2021 Mar 8;15(1):106. doi: 10.1186/s13256-021-02732-6.
10
Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents.新型嘧啶衍生物作为抗癌剂的设计、合成与生物评价。
Molecules. 2021 Feb 2;26(3):771. doi: 10.3390/molecules26030771.